There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) and Dexcom (DXCM – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioLife Solutions (BLFS)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on BioLife Solutions yesterday. The company’s shares closed last Wednesday at $26.13.
According to TipRanks.com, Hewitt is a 1-star analyst with an average return of
BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $30.38.
See today’s best-performing stocks on TipRanks >>
Dexcom (DXCM)
In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Dexcom, with a price target of $105.00. The company’s shares closed last Wednesday at $66.08, close to its 52-week low of $62.34.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $97.90 average price target, representing a 45.7% upside. In a report issued on September 17, Citi also maintained a Buy rating on the stock.
Read More on BLFS:
Disclaimer & DisclosureReport an Issue
- BioLife Solutions management to meet virtually with KeyBanc
- BioLife Solutions Holds Annual Stockholders Meeting
- BioLife Solutions Reports Strong Q2 Growth Amid Challenges
- BioLife Solutions: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- BioLife Solutions price target raised to $32 from $30 at H.C. Wainwright
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
